Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,209,063
  • Shares Outstanding, K 118,474
  • Annual Sales, $ 1,397 M
  • Annual Income, $ 316,890 K
  • EBIT $ 594 M
  • EBITDA $ 687 M
  • 60-Month Beta 1.03
  • Price/Sales 5.65
  • Price/Cash Flow 13.97
  • Price/Book 160.54

Options Overview Details

View History
  • Implied Volatility 31.96% (-4.44%)
  • Historical Volatility 30.43%
  • IV Percentile 4%
  • IV Rank 10.97%
  • IV High 52.70% on 08/05/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 25) 6.04 (8.66%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 490
  • Volume Avg (30-Day) 433
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 11,857
  • Open Int (30-Day) 11,430
  • Expected Range 63.78 to 75.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.49
  • Number of Estimates 4
  • High Estimate $1.55
  • Low Estimate $1.45
  • Prior Year $1.03
  • Growth Rate Est. (year over year) +44.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.33 +13.44%
on 03/27/26
70.31 -1.05%
on 04/20/26
+6.14 (+9.68%)
since 03/20/26
3-Month
61.33 +13.44%
on 03/27/26
82.22 -15.39%
on 02/09/26
-0.86 (-1.22%)
since 01/20/26
52-Week
47.50 +46.46%
on 05/14/25
82.22 -15.39%
on 02/09/26
+10.78 (+18.34%)
since 04/17/25

Most Recent Stories

More News
3 Cash-Producing Stocks with Exciting Potential

3 Cash-Producing Stocks with Exciting Potential

FOUR : 49.32 (-0.68%)
PTEN : 9.77 (+3.72%)
HALO : 69.57 (+0.40%)
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore

2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore

S : 14.32 (+2.14%)
VSH : 26.33 (+1.58%)
HALO : 69.57 (+0.40%)
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off

OLPX : 2.04 (+0.49%)
REZI : 39.97 (-0.77%)
HALO : 69.57 (+0.40%)
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

SAN DIEGO , April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into...

HALO : 69.57 (+0.40%)
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

HALO : 69.57 (+0.40%)
Halozyme Appoints David Ramsay as Interim Chief Financial Officer

SAN DIEGO , March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer...

HALO : 69.57 (+0.40%)
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens

HALO : 69.57 (+0.40%)
Halozyme to Participate in Upcoming Investor Conferences

SAN DIEGO , Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present...

HALO : 69.57 (+0.40%)
2 Reasons to Like HALO (and 1 Not So Much)

2 Reasons to Like HALO (and 1 Not So Much)

HALO : 69.57 (+0.40%)
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

HALO : 69.57 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 72.39
2nd Resistance Point 70.92
1st Resistance Point 70.10
Last Price 69.57
1st Support Level 67.81
2nd Support Level 66.34
3rd Support Level 65.52

See More

52-Week High 82.22
Last Price 69.57
Fibonacci 61.8% 68.96
Fibonacci 50% 64.86
Fibonacci 38.2% 60.76
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.